GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » Net Change in Cash

Crescita Therapeutics (TSX:CTX) Net Change in Cash : C$-0.61 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Crescita Therapeutics's Net Change in Cash for the three months ended in Mar. 2024 was C$0.15 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.61 Mil.

Crescita Therapeutics Net Change in Cash Historical Data

The historical data trend for Crescita Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics Net Change in Cash Chart

Crescita Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 5.01 -2.95 -3.09 1.15

Crescita Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 -0.05 -0.18 -0.53 0.15

Crescita Therapeutics Net Change in Cash Calculation

Crescita Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=2.076+-0.133+-0.782+-0.014
=1.15

Crescita Therapeutics's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.378+0+-0.236+0.004
=0.15

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (TSX:CTX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » Net Change in Cash
Comparable Companies
XCNQ:XTRX TSX:VPH XCNQ:CANN TSX:XLY TSXV:MPH XCNQ:RVV XCNQ:BAMM TSX:WLLW XCNQ:SLNG NEOE:TILT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
CRRTF:USA
Address
2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Website
https://www.crescitatherapeutics.com
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.
Executives
Knight Therapeutics Inc. 10% Security Holder

Crescita Therapeutics (TSX:CTX) Headlines

No Headlines